Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Black Titan Corp (BTTC)

Black Titan Corp (BTTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Black Titan Corp 10 EAST 53RD STREET SUITE 3001 NEW YORK NY 10022 USA

www.titanpharm.com P: 650-244-4990

Sector:

Medical

Description:

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Key Statistics

Overview:

Market Capitalization, $K 14,391
Enterprise Value, $K 11,561
Shares Outstanding, K 9,994
Float, K 9,922
% Float 99.28%
Short Interest, K 91
Short Float 0.91%
Days to Cover 1.00
Short Volume Ratio 0.42
% of Insider Shareholders 0.72%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 2,683 K
Annual Net Income, $ -4,710 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -690 K
EBIT, $ -2,610 K
EBITDA, $ -2,600 K

Growth:

1-Year Return -93.99%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 98.79%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.65 on 08/14/25
Next Earnings Date 05/13/26
Earnings Per Share ttm -2.95
EPS Growth vs. Prev Qtr -4.84%
EPS Growth vs. Prev Year 71.62%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

BTTC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 3.92
Price/Cash Flow N/A
Price/Book 0.61
Book Value/Share 2.10
Interest Coverage -0.03
60-Month Beta 1.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.